The multiplex immunohistochemistry (mIHC) platform provides an automated, tissue sparing and cost- effective solution for multiplex analysis of up 23 immune markers on a single FFPE slide. mIHC analysis allows for thorough investigation of in situ immune contexture of tumor and stroma.

The multiplex approach allows for prospective and retrospective monitoring of clinical tissue samples:
  • Baseline, in response to standard of care treatment, in response to immune treatment and longitudinal biopsies
  • Primary (early and late stage) and metastatic disease
  • Predictive biomarkers for treatment stratification
  • Identification of response vs resistance to treatment
  • On treatment changes in response to treatment

Methodology:
mIHC utilizes chromogen based immuno-detection and antibody stripping chemistry. mIHC antibody panels have been validated using single staining comparisons to multiplex staining on positive control tissues. Automated staining reduces batch variability and inclusion of positive control tissues in every staining batch assure accuracy. This technique offers deep, rapid and automated immune auditing
emphasizing spatial information. Panels are validated in brain, lung, liver, skin, pancreas, breast, lymph node, head and neck, and bone marrow tissue.
IMCO_top_MIHCoverview

IMCO_bottom_MIHCoverview


Discovery 23 panel:
Discovery Panel Analysis Chart


Discovery 23 panel results help guide subsequent deeper analysis with additional mIHC panels:
Orange_blue_MIHCpanels

CUSTOM PANELS AND TISSUE SPECIFIC VALIDATION ARE AVAILABLE.

Specimen Requirements:
          mIHC analysis is compatible with FFPE tissue or 20 gage needle core biopsy

See Our List of Available panels

Multiplex IHC Data Visualization and Interpretation Examples

Custom Panels Available Upon Request: IMCO@ohsu.edu

Innovations in Testing
Cutting Edge Assays and Analytics
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More